Search This Blog

Saturday, February 6, 2016

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction



Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.